Investigational drugs for Diabetic nephropathy

Monica Cortinovis, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Background: Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality. Objective: Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/ albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents. However, the renoprotection provided by these treatments is only partial, calling for more effective approaches. Methods: This review examines emerging strategies for the treatment of diabetic nephropathy, including aggressive RAAS blockade, statins, glitazones, ruboxistaurin, and other promising agents. Results/conclusions: In diabetic patients with overt nephropathy, multipharmacological interventions represent a promising way to prevent progression to ESRD. Results of ongoing trials are needed to estblish whether the current standard of care of diabetic nephropathy might be improved with these new strategies.

Original languageEnglish
Pages (from-to)1487-1500
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Investigational Drugs
Diabetic Nephropathies
Renin-Angiotensin System
Chronic Kidney Failure
ruboxistaurin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thiazolidinediones
Albuminuria
Standard of Care
Proteinuria
Therapeutics
Blood Pressure
Morbidity
Mortality

Keywords

  • Chronic kidney disease
  • Diabetic nephropathy
  • Renin-angiotensin-aldosterone system
  • Renoprotective agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational drugs for Diabetic nephropathy. / Cortinovis, Monica; Cattaneo, Dario; Perico, Norberto; Remuzzi, Giuseppe.

In: Expert Opinion on Investigational Drugs, Vol. 17, No. 10, 10.2008, p. 1487-1500.

Research output: Contribution to journalArticle

Cortinovis, Monica ; Cattaneo, Dario ; Perico, Norberto ; Remuzzi, Giuseppe. / Investigational drugs for Diabetic nephropathy. In: Expert Opinion on Investigational Drugs. 2008 ; Vol. 17, No. 10. pp. 1487-1500.
@article{bdca9780e771487c85b6d29cce70f6ae,
title = "Investigational drugs for Diabetic nephropathy",
abstract = "Background: Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality. Objective: Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/ albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents. However, the renoprotection provided by these treatments is only partial, calling for more effective approaches. Methods: This review examines emerging strategies for the treatment of diabetic nephropathy, including aggressive RAAS blockade, statins, glitazones, ruboxistaurin, and other promising agents. Results/conclusions: In diabetic patients with overt nephropathy, multipharmacological interventions represent a promising way to prevent progression to ESRD. Results of ongoing trials are needed to estblish whether the current standard of care of diabetic nephropathy might be improved with these new strategies.",
keywords = "Chronic kidney disease, Diabetic nephropathy, Renin-angiotensin-aldosterone system, Renoprotective agents",
author = "Monica Cortinovis and Dario Cattaneo and Norberto Perico and Giuseppe Remuzzi",
year = "2008",
month = "10",
doi = "10.1517/13543784.17.10.1487",
language = "English",
volume = "17",
pages = "1487--1500",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Investigational drugs for Diabetic nephropathy

AU - Cortinovis, Monica

AU - Cattaneo, Dario

AU - Perico, Norberto

AU - Remuzzi, Giuseppe

PY - 2008/10

Y1 - 2008/10

N2 - Background: Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality. Objective: Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/ albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents. However, the renoprotection provided by these treatments is only partial, calling for more effective approaches. Methods: This review examines emerging strategies for the treatment of diabetic nephropathy, including aggressive RAAS blockade, statins, glitazones, ruboxistaurin, and other promising agents. Results/conclusions: In diabetic patients with overt nephropathy, multipharmacological interventions represent a promising way to prevent progression to ESRD. Results of ongoing trials are needed to estblish whether the current standard of care of diabetic nephropathy might be improved with these new strategies.

AB - Background: Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality. Objective: Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/ albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents. However, the renoprotection provided by these treatments is only partial, calling for more effective approaches. Methods: This review examines emerging strategies for the treatment of diabetic nephropathy, including aggressive RAAS blockade, statins, glitazones, ruboxistaurin, and other promising agents. Results/conclusions: In diabetic patients with overt nephropathy, multipharmacological interventions represent a promising way to prevent progression to ESRD. Results of ongoing trials are needed to estblish whether the current standard of care of diabetic nephropathy might be improved with these new strategies.

KW - Chronic kidney disease

KW - Diabetic nephropathy

KW - Renin-angiotensin-aldosterone system

KW - Renoprotective agents

UR - http://www.scopus.com/inward/record.url?scp=52949106154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949106154&partnerID=8YFLogxK

U2 - 10.1517/13543784.17.10.1487

DO - 10.1517/13543784.17.10.1487

M3 - Article

C2 - 18808309

AN - SCOPUS:52949106154

VL - 17

SP - 1487

EP - 1500

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -